US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.16 against a street estimate of 0.16 — a beat of 0.0%.
Analysts rate Bausch + Lomb Corp a buy (6 buy, 8 hold, 1 sell out of 15) with an average price target of $18.54.
| Fund | Stake |
|---|---|
| Deutsche Bank AG | 0.99% |
| ICAHN CARL C | 0.98% |
| Oaktree Capital Management LLC | 0.95% |
| D. E. Shaw & Co LP | 0.88% |
| Goldentree Asset Management LP | 0.74% |
| Silver Point Capital LP | 0.63% |
| Davidson Kempner Capital Management LP | 0.62% |
| Caspian Capital Partners, L.P. | 0.56% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-29 |
| Shareholder vote results · Q2 2026 | 2026-05-20 |
| Quarterly report · Q1 2026 | 2026-04-29 |
| Results announced · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Annual report FY2025 | 2026-02-18 |
| Results announced · Q1 2026 | 2026-02-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bausch + Lomb Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.